#Aav-Gene-Therapy

3 stories

Regulatory August 25, 2026 · View digest

Regenxbio (NASDAQ: RGNX) Shares Fell Approximately 25% to $8.05 Tuesday August 25, 2026 After the FDA Placed a Clinical Hold on the RGX-121 Gene Therapy Program for the Treatment of Mucopolysaccharidosis Type II (MPS II, Also Known as Hunter Syndrome, a Rare X-Linked Lysosomal Storage Disease Caused by Iduronate-2-Sulfatase (IDS) Deficiency That Results in Accumulation of Glycosaminoglycans in Multiple Tissues Including the Central Nervous System, With Progressive Cognitive Decline, Skeletal Abnormalities, and Cardiac and Respiratory Involvement in the Severe Neuronopathic Form); RGX-121 Is an AAV Gene Therapy Delivering an IDS-Encoding Transgene Via Intracerebroventricular Administration Designed to Address the Neurocognitive Manifestations That the Currently-Approved Enzyme Replacement Therapy Elaprase (Idursulfase) Does Not Reach

Regenxbio (NASDAQ: RGNX) shares fell approximately 25% to $8.05 Tuesday August 25, 2026 after the FDA placed a clinical hold on the RGX-121 gene therapy program for the treatment of Mucopolysaccharidosis type II (MPS II, also known as Hunter Syndrome). Disease context: MPS II is a rare X-linked lysosomal storage disease affecting approximately 1 in 100,000-170,000 male births globally, caused by iduronate-2-sulfatase (IDS) enzyme deficiency that results in accumulation of glycosaminoglycans (GAGs) in multiple tissues including the central nervous system. Clinical manifestations include progressive cognitive decline, skeletal abnormalities, cardiac and respiratory involvement, and reduced life expectancy in the severe neuronopathic form (approximately two-thirds of patients). RGX-121 mechanism: an AAV (adeno-associated virus) gene therapy delivering an IDS-encoding transgene via intracerebroventricular administration designed to establish stable IDS expression in the central nervous system, addressing the neurocognitive manifestations that the currently-approved enzyme replacement therapy Elaprase (idursulfase, Takeda) does not reach because Elaprase administered intravenously does not cross the blood-brain barrier. Specific reasons for the FDA clinical hold have not been publicly disclosed by Regenxbio; details are expected in subsequent regulatory correspondence. The clinical hold delays but does not necessarily preclude the RGX-121 development pathway. Regenxbio's broader pipeline includes RGX-202 for Duchenne muscular dystrophy in Phase 3, RGX-314 for wet AMD in Phase 3, and multiple additional gene therapy candidates.

Clinical Trials July 13, 2026 · View digest

Voyager Therapeutics Discloses Updated Six-Month GLP Non-Human Primate Toxicology Data for VY1706 (Tau-Targeted Blood-Brain-Barrier-Crossing AAV Gene Therapy) at AAIC 2026 Monday July 13: Single Intravenous Dose Delivered Sustained Tau Protein Reduction Up to 75% in Key Brain Regions of NHPs Through Six Months (Extending the Prior 64% Reduction at Three Months), With No Adverse Clinical Pathology, No AAV Liver Transaminase Elevations, Stable Plasma Neurofilament Levels, and No Cellular Immune Activations; Initiation of Clinical Trial in Adults With Early Alzheimer's Disease Remains Expected in Second Half of 2026 Following FDA IND Clearance

Voyager Therapeutics (NASDAQ: VYGR) presented six-month Good Laboratory Practice (GLP) toxicology data for VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting tau for Alzheimer's disease, in a Developing Topics late-breaking poster at AAIC 2026 in London on Monday July 13, 2026. The updated six-month data extends the prior three-month timepoint (64% reduction reported earlier this month): a single intravenous dose delivered sustained tau protein reduction up to 75% in key brain regions of non-human primates over six months. VY1706 was well tolerated with no adverse clinical pathology and no histopathological findings up to the highest dose tested. Notably, the program showed none of the typical AAV liver transaminase elevations at any dose level throughout six months, plasma neurofilament levels remained generally stable with no dose-related increases, and there were no cellular immune activations. Voyager received FDA Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026.

Clinical Trials July 12, 2026 · View digest

Voyager Therapeutics Presents VY1706 (Tau-Targeted Blood-Brain-Barrier-Crossing AAV Gene Therapy) Developing Topics Poster at AAIC 2026 (July 12-15 London): GLP Non-Human Primate Toxicology Study Data Show Single Intravenous Dose Well Tolerated Up to 5E13 vg/kg With Up to 64% Tau Reduction in Key Brain Regions at 13 Weeks; FDA IND Cleared, First-in-Human Alzheimer's Disease Clinical Trial Dosing Expected Second Half of 2026

Voyager Therapeutics (NASDAQ: VYGR) presented Developing Topics late-breaking poster data at AAIC 2026 in London (July 12-15) featuring VY1706, its investigational blood-brain-barrier-crossing AAV gene therapy targeting intracellular and extracellular tau for Alzheimer's disease. The 3-month GLP non-human primate toxicology study showed VY1706 was well tolerated at a single intravenous dose up to the highest level tested (5E13 vg/kg), with no adverse clinical pathology or histopathological findings. Tau protein was reduced up to 64% in key brain regions of non-human primates at 13 weeks following a single IV dose. Voyager received FDA Investigational New Drug (IND) clearance for VY1706 in H1 2026, enabling initiation of a clinical trial in adults with early Alzheimer's disease with dosing expected in the second half of 2026. The program extends the same BBB-delivery-plus-tau-reduction thesis that Denali's DNL628 OTV pursues via anti-tau ASO; both address the same therapeutic hypothesis through different modalities (AAV gene therapy vs. anti-sense oligonucleotide).